Recommended Dosing for Trelegy in COPD and Asthma
The recommended dose of Trelegy (fluticasone furoate, umeclidinium, vilanterol) is one inhalation once daily for both COPD and asthma treatment. 1
Dosing for COPD
- Trelegy Ellipta is approved as a once-daily maintenance treatment for adults with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) 2
- The standard dose contains fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg in a single dry powder inhaler 3
- Trelegy should be administered at the same time each day to maintain consistent blood levels 1
- The medication should not be used more often than recommended or at higher doses, as this could lead to clinically significant cardiovascular effects 1
Dosing for Asthma
- For asthma management, Trelegy is also administered as one inhalation once daily 1
- The asthma formulation contains fluticasone furoate 200 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg 4
- Patients should not use more than one inhalation once daily of Trelegy for asthma control 1
Important Administration Considerations
- Trelegy is not intended for the relief of acute symptoms (rescue therapy) and should not be used for treating acute episodes of bronchospasm 1
- Patients should be instructed to rinse their mouth with water without swallowing following administration to reduce the risk of oropharyngeal candidiasis 1
- When beginning treatment with Trelegy, patients who have been taking short-acting beta2-agonists on a regular basis should be instructed to discontinue regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms 1
Monitoring and Precautions
- Monitor patients periodically for oropharyngeal candidiasis, which may require treatment with appropriate antifungal therapy 1
- An increased incidence of pneumonia has been observed in COPD patients receiving fluticasone furoate/vilanterol; healthcare providers should remain vigilant for possible development of pneumonia 1
- Patients should not use Trelegy in conjunction with other therapies containing LABA, as this could result in overdose 1
Special Considerations
- If Trelegy no longer controls symptoms of bronchoconstriction, the patient's short-acting beta2-agonist becomes less effective, or the patient needs more short-acting beta2-agonist than usual, these may be markers of disease deterioration requiring immediate reevaluation 1
- The daily dose should not be increased beyond the recommended one inhalation once daily 1
- The ELLIPTA inhaler delivery system may help improve adherence due to its once-daily dosing schedule and ease of use 4, 5